Post-booster longitudinal plasma proteomic changes following BNT162b2 COVID-19 vaccination in Qatar
Sana Bentebbal·Julie Decock·Bakhita Meqbel·Abdullah Aldushain·Alberto de la Fuente·Neyla S. Al-Akl·Houda Y. A. Moussa·Kyung C. Shin·Rowaida Z. Taha·Mohammed Abukhattab·Muna A. Al-Maslamani·Nehad M. Alajez·Abdelilah Arredouani·Yongsoo Park·Sara A. Abdulla·Omar M. A. El-Agnaf·Houari B. Abdesselem·Ali S. Omrani·Ilham Bensmail·Remy Thomas·Adviti Naik·Hibah Shaath·Abdi Adam·Ahmed Zaqout
Background The COVID-19 pandemic imposed a major global health and economic burden. Although the pandemic was no longer declared a public health emergency of international concern in May 2023, SARS-CoV-2 variants continue to emerge, and millions remain affected by long COVID. This raises the question whether continued vaccination provides lasting benefits in preventing viral transmission and severe illness. Aim This longitudinal study assessed the effects of the third BNT162b2 mRNA vaccine dose